Implication of Critical Pharmacokinetic Gene Variants on Therapeutic Response to Metformin in Type 2
- 19 June 2018
- journal article
- research article
- Published by Taylor & Francis in Pharmacogenomics
- Vol. 19 (11) , 905-911
Abstract
Aim: Metformin, an oral hypoglycemic drug is the first line of treatment for Type 2 diabetes individuals. We studied the effect of critical gene single nucleotide polymorphisms on the glucose lowering effect of metformin. Method: We performed a prospective study on 221 newly diagnosed, treatment-naive Type 2 diabetes subjects. Individuals were started with metformin monotherapy and followed up for 12 weeks. Results: Our association analysis revealed that SLC22A2 rs316019 and SLC47A2 rs12943590 were significantly associated with metformin drug response across co-dominant and dominant models, respectively. SLC22A2 rs316019 GG and SLC47A2 rs12943590 GA combined genotypes showed maximum average change in HbA1c level. Conclusion: The present study proposes a role of SLC22A2 rs316019 and SLC47A2 rs12943590 in the pharmacokinetic action of metformin.Keywords
Funding Information
- Indian Council of Medical Research
- Technology Information Forecasting and Assessment Council-Centre of Relevance and Excellence (EMR/2015/002384)
- Dr TMA Pai Endowment Chair in Pharmacogenomics
- Manipal Academy of Higher Education
This publication has 23 references indexed in Scilit:
- Influence of SLC22A1 rs622342 genetic polymorphism on metformin response in South Indian type 2 diabetes mellitus patientsClinical and Experimental Medicine, 2014
- Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)Diabetologia, 2012
- Effect of genetic variation in the organic cation transporter 2 on the renal elimination of metforminPharmacogenetics and Genomics, 2009
- Genetic variation in the organic cation transporter 1 is associated with metformin response in patients with diabetes mellitusThe Pharmacogenomics Journal, 2009
- Effect of Genetic Variation in the Organic Cation Transporter 1, OCT1, on Metformin PharmacokineticsClinical Pharmacology & Therapeutics, 2007
- Substrate specificity of MATE1 and MATE2-K, human multidrug and toxin extrusions/H+-organic cation antiportersBiochemical Pharmacology, 2007
- Cytochrome P450 2C9 *2 and *3 Polymorphisms and the Dose and Effect of Sulfonylurea in Type II Diabetes MellitusClinical Pharmacology & Therapeutics, 2007
- Glycemic Durability of Rosiglitazone, Metformin, or Glyburide MonotherapyNew England Journal of Medicine, 2006
- Drug specificity and intestinal membrane localization of human organic cation transporters (OCT)Biochemical Pharmacology, 2005
- An efficient procedure for genotyping single nucleotide polymorphismsNucleic Acids Research, 2001